These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9713408)

  • 41. The United States Renal Data System's 1991 annual data report: an introduction.
    Held PJ; Port FK; Webb RL; Wolfe RA; Garcia JR; Blagg CR; Agodoa LY
    Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):1-16. PubMed ID: 1951350
    [No Abstract]   [Full Text] [Related]  

  • 42. New chapter on CKD highlights changes to 15th annual USRDS report.
    Nephrol News Issues; 2003 Nov; 17(12):25-8, 110. PubMed ID: 14640007
    [No Abstract]   [Full Text] [Related]  

  • 43. Role of dialysis dose on morbidity and mortality in maintenance hemodialysis patients.
    Parker TF
    Am J Kidney Dis; 1994 Dec; 24(6):981-9. PubMed ID: 7985680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Why we need the option of more dialysis.
    Hodge MH
    Nephrol News Issues; 2006 Oct; 20(11):76, 78-9. PubMed ID: 17039973
    [No Abstract]   [Full Text] [Related]  

  • 45. CROWNWeb: the evolution of kidney data management. Part 3 of a three-part series.
    McDonough MJ
    Nephrol News Issues; 2008 Sep; 22(10):48-50. PubMed ID: 18814557
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results.
    St Peter WL; Liu J; Weinhandl ED; Fan Q
    Hemodial Int; 2008 Oct; 12(4):480-91. PubMed ID: 19090871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Underreporting of nursing home utilization on the CMS-2728 in older incident dialysis patients and implications for assessing mortality risk.
    Bowling CB; Zhang R; Franch H; Huang Y; Mirk A; McClellan WM; Johnson TM; Kutner NG
    BMC Nephrol; 2015 Mar; 16():32. PubMed ID: 25880589
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Renal replacement therapy in the United States: data from the United States Renal Data System.
    Agodoa LY; Eggers PW
    Am J Kidney Dis; 1995 Jan; 25(1):119-33. PubMed ID: 7810518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison of transplant outcomes in peritoneal and hemodialysis patients.
    Snyder JJ; Kasiske BL; Gilbertson DT; Collins AJ
    Kidney Int; 2002 Oct; 62(4):1423-30. PubMed ID: 12234315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Proposed Stark II regulations unveiled. HCFA interpretation of self-referral rules recognize circumstances of dialysis providers.
    Riley JB; Pristave RJ
    Nephrol News Issues; 1998 Jun; 12(6):13-5. PubMed ID: 9697471
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states.
    Thamer M; Richard C; Ray NF; Greer JW; Cotter DJ; Pearson BC
    Am J Kidney Dis; 1996 Aug; 28(2):235-49. PubMed ID: 8768919
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decoding Acute Myocardial Infarction among Patients on Dialysis.
    Howard CE; McCullough PA
    J Am Soc Nephrol; 2017 May; 28(5):1337-1339. PubMed ID: 28404663
    [No Abstract]   [Full Text] [Related]  

  • 53. Comorbidity ascertainment from the ESRD Medical Evidence Report and Medicare claims around dialysis initiation: a comparison using US Renal Data System data.
    Krishnan M; Weinhandl ED; Jackson S; Gilbertson DT; Lacson E
    Am J Kidney Dis; 2015 Nov; 66(5):802-12. PubMed ID: 26015277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New HCFA rule may impact social work services in ESRD facilities.
    Callahan MB
    Nephrol News Issues; 1998 Sep; 12(9):10-1. PubMed ID: 9923290
    [No Abstract]   [Full Text] [Related]  

  • 55. Upper arm arteriovenous fistula for chronic hemodialysis: 20 years later.
    Dagher FJ
    Transplant Proc; 1996 Aug; 28(4):2325-7. PubMed ID: 8769238
    [No Abstract]   [Full Text] [Related]  

  • 56. Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline: response to Burrows, Li, and Geiss.
    Villar E; McDonald SP; Couchoud C
    Diabetes Care; 2010 May; 33(5):e69; author reply e70. PubMed ID: 20427678
    [No Abstract]   [Full Text] [Related]  

  • 57. Frailty in end-stage renal disease: comparing patient, caregiver, and clinician perspectives.
    Clark DA; Khan U; Kiberd BA; Turner CC; Dixon A; Landry D; Moffatt HC; Moorhouse PA; Tennankore KK
    BMC Nephrol; 2017 May; 18(1):148. PubMed ID: 28464924
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reports from the ESRD Networks.
    Adv Ren Replace Ther; 2000 Oct; 7(4 Suppl 1):S1-S104. PubMed ID: 11184738
    [No Abstract]   [Full Text] [Related]  

  • 59. Methods of ESRD treatment.
    Am J Kidney Dis; 1991 Nov; 18(5 Suppl 2):38-48. PubMed ID: 1951356
    [No Abstract]   [Full Text] [Related]  

  • 60. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.